Antipsychotics and Gene Expression in Soft Tissues

Exclusion Criteria

• •Personal or family history (parents and siblings) of diabetes or other metabolic diseases, relevant diseases as defined by the investigator.
• •History of hypertension, blood pressure \> 140/90 at screening, cardiovascular disease.
• •Body mass index out of the range of \<18 and \>25 kg/m.
• •Human immunodeficiency virus (HIV) or Hepatitis B/C positive virology.
• •Allergy or hypersensitivity against olanzapine/ziprasidone or another excipient.
• •Contraindications against the use of the drug according to the Summary of Product Characteristics (SmPC).
• •Any drug intake 2 weeks prior to first study day.
• •History of excessive bleeding tendency/hemophilia.
• •Presence of relevant illness within the last 3 weeks.
• •Currently enrolled into an other clinical study with Investigational Medicinal Products (IMPs).
• •Last study participation less than 4 weeks.
• •Suspected non-compliance with study instructions and life-style requirements.
• •History of alcohol or drug abuse.
• •Blood/Plasma donation within 4 weeks prior to study day.
• •Previous exposure to antipsychotic drugs.
• •Nicotine consumption at time of enrolment (at least 3 months of non-smoking required).